RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000075.xml
PDF herunterladen
Semin Respir Crit Care Med 2022; 43(04): 552-558
DOI: 10.1055/s-0042-1747939
DOI: 10.1055/s-0042-1747939
Review Article
Endoscopic Options for Moderate COPD, Chronic Bronchitis, and Uncontrolled Asthma
Abstract
Until now, interventional therapies for patients with chronic obstructive pulmonary disease have been available in the form of lung volume reduction procedures as end-stage options. Currently, the range of indications is expanding to include earlier stages of the diseases. Lung denervation is available for moderate COPD, and patients with chronic bronchitis are being evaluated for endoscopic goblet cell ablation. Rheoplasty, metered spray cryo technique, and Karakoca resector balloon are used for this indication. But also, for patients with severe uncontrolled asthma, several techniques are available today. In addition to thermoplasty as a long-proven procedure, new and currently under investigation is the targeted lung denervation.
Most of these techniques are currently being tested in large pivotal trials and it will soon become clear in which phenotype which technique will be used in the different forms and stages of obstructive diseases. The current paper presents the techniques and the currently available literature.
Keywords -
COPD -
rheoplasty -
targeted lung denervation
Publikationsverlauf
Artikel online veröffentlicht:
01. Juni 2022
© 2022. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Wahidi MM, Herth FJ, Ernst A. State of the art: interventional pulmonology. Chest 2007; 131 (01) 261-274
- 2 Toma TP, Hopkinson NS, Hillier J. et al. Bronchoscopic volume reduction with valve implants in patients with severe emphysema. Lancet 2003; 361 (9361): 931-933
- 3 Herth FJ. Endoscopic asthma therapy. Sense and nonsense. Internist (Berl) 2008; 49 (11) 1320-1322 , 1324–1325
- 4 Cox PG, Miller J, Mitzner W, Leff AR. Radiofrequency ablation of airway smooth muscle for sustained treatment of asthma: preliminary investigations. Eur Respir J 2004; 24 (04) 659-663
- 5 Vogelmeier CF, Criner GJ, Martinez FJ. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Eur Respir J 2017; 49 (03) 1700214
- 6 Vogelmeier C, Hederer B, Glaab T. et al; POET-COPD Investigators. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011; 364 (12) 1093-1103
- 7 van Geffen WH, Kerstjens HAM, Slebos DJ. Emerging bronchoscopic treatments for chronic obstructive pulmonary disease. Pharmacol Ther 2017; 179: 96-101
- 8 Hansel TT, Barnes PJ. Tiotropium bromide: a novel once-daily anticholinergic bronchodilator for the treatment of COPD. Drugs Today (Barc) 2002; 38 (09) 585-600
- 9 Gompelmann D, Eberhardt R, Herth FJ. Novel endoscopic approaches to treating chronic obstructive pulmonary disease and emphysema. Semin Respir Crit Care Med 2015; 36 (04) 609-615
- 10 Hummel JP, Mayse ML, Dimmer S, Johnson PJ. Physiologic and histopathologic effects of targeted lung denervation in an animal model. J Appl Physiol (1985) 2019; 126 (01) 67-76
- 11 Slebos DJ, Klooster K, Koegelenberg CF. et al. Targeted lung denervation for moderate to severe COPD: a pilot study. Thorax 2015; 70 (05) 411-419
- 12 Valipour A, Shah PL, Pison C. et al; On behalf of the AIRFLOW-1 Study Group. Safety and dose study of targeted lung denervation in moderate/severe COPD patients. Respiration 2019; 98 (04) 329-339
- 13 Slebos DJ, Shah PL, Herth FJF. et al; AIRFLOW-2 Study Group. Safety and adverse events after targeted lung denervation for symptomatic moderate to severe chronic obstructive pulmonary disease (AIRFLOW). A multicenter randomized controlled clinical trial. Am J Respir Crit Care Med 2019; 200 (12) 1477-1486
- 14 Poletti V, Vancheri C, Albera C. et al; FIBRONET study group. Clinical course of IPF in Italian patients during 12 months of observation: results from the FIBRONET observational study. Respir Res 2021; 22 (01) 66
- 15 Valipour A, Shah PL, Herth FJ. et al; AIRFLOW-2 Trial Study Group. Two-year outcomes for the double-blind, randomized, sham-controlled study of targeted lung denervation in patients with moderate to severe COPD: AIRFLOW-2. Int J Chron Obstruct Pulmon Dis 2020; 15: 2807-2816
- 16 Slebos DJ, Degano B, Valipour A, Shah PL, Deslée G, Sciurba FC. AIRFLOW-3 Trial Study Group. Design for a multicenter, randomized, sham-controlled study to evaluate safety and efficacy after treatment with the Nuvaira® lung denervation system in subjects with chronic obstructive pulmonary disease (AIRFLOW-3). BMC Pulm Med 2020; 20 (01) 41
- 17 Elbehairy AF, Raghavan N, Cheng S. et al; Canadian Respiratory Research Network. Physiologic characterization of the chronic bronchitis phenotype in GOLD grade IB COPD. Chest 2015; 147 (05) 1235-1245
- 18 Kim V, Criner GJ. Chronic bronchitis and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187 (03) 228-237
- 19 Cerveri I, Accordini S, Verlato G. et al; European Community Respiratory Health Survey (ECRHS) Study Group. Variations in the prevalence across countries of chronic bronchitis and smoking habits in young adults. Eur Respir J 2001; 18 (01) 85-92
- 20 Widysanto A, Mathew G. Chronic Bronchitis. Treasure Island, FL: StatPearls; 2021
- 21 Hartman JE, Klooster K, Augustijn SWS. et al. Identifying responders and exploring mechanisms of action of the endobronchial coil treatment for emphysema. Respiration 2021; 100 (05) 443-451
- 22 Fernandez-Bussy S, VandorLaan P, Ing A. et al. Histopathologic results post bronchial rheoplasty. Am J Respir Crit Care Med 2019; 199: A7043
- 23 Valipour A, Fernandez-Bussy S, Ing AJ. et al. Bronchial rheoplasty for treatment of chronic bronchitis. Twelve-month results from a multicenter clinical trial. Am J Respir Crit Care Med 2020; 202 (05) 681-689
- 24 Garner JL, Shaipanich T, Hartman JE. et al. A prospective safety and feasibility study of metered cryospray for patients with chronic bronchitis in COPD. Eur Respir J 2020; 56 (06) 2000556
- 25 Karakoca Y, Karaagac G, Aydemir C. Therapeutic bronchoscopic intervention with resector balloon. J Bronchology Interv Pulmonol 2009; 16 (02) 78-80
- 26 Karakoca Y, Karaagac G, Aydemir C, Caner C. A new endoluminal resection technique and device: resector balloon. Ann Thorac Surg 2008; 85 (02) 628-631
- 27 Karakoca Y, Gogus G, Akduman S, Erturk B. Follow-up outcomes of chronic obstructive pulmonary disease patients who underwent dilatation and curettage with the Karakoca resector balloon: a 188-case series over 5 years. Medicine (Baltimore) 2018; 97 (48) e13400
- 28 Karakoca Y, Karaagac Gogus G, Yapicier O. Use of resector balloon desobstruction in patients with severe chronic obstructive pulmonary disease: a pilot feasibility study on a novel desobstruction technique. J Bronchology Interv Pulmonol 2015; 22 (03) 209-214
- 29 Martin RJ, Bel EH, Pavord ID, Price D, Reddel HK. Defining severe obstructive lung disease in the biologic era: an endotype-based approach. Eur Respir J 2019; 54 (05) 1900108
- 30 Boulet LP, Reddel HK, Bateman E, Pedersen S, FitzGerald JM, O'Byrne PM. The Global Initiative for Asthma (GINA): 25 years later. Eur Respir J 2019; 54 (02) 1900598
- 31 Langton D, Lee P. Bronchial thermoplasty: redefining its role. Respirology 2020; 25 (09) 981-986
- 32 Wahidi MM, Herth FJF, Chen A, Cheng G, Yarmus L. State of the art: interventional pulmonology. Chest 2020; 157 (03) 724-736
- 33
Castro M,
Rubin AS,
Laviolette M.
et al;
AIR2 Trial Study Group.
Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma:
a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir
Crit Care Med 2010; 181 (02) 116-124
MissingFormLabel
- 34
Chaudhuri R,
Rubin A,
Sumino K.
et al;
BT10+ Study Group.
Safety and effectiveness of bronchial thermoplasty after 10 years in patients with
persistent asthma (BT10+): a follow-up of three randomised controlled trials. Lancet
Respir Med 2021; 9 (05) 457-466
MissingFormLabel
- 35 Dyrda P, Tazzeo T, DoHarris L. et al. Acute response of airway muscle to extreme temperature includes disruption of actin-myosin interaction. Am J Respir Cell Mol Biol 2011; 44 (02) 213-221
- 36 Vaselli M, Wijsman PC, Willemse J. et al. Polarization sensitive optical coherence tomography for bronchoscopic airway smooth muscle detection in bronchial thermoplasty-treated patients with asthma. Chest 2021; 160 (02) 432-435
- 37 Ichikawa T, Panariti A, Audusseau S. et al. Effect of bronchial thermoplasty on structural changes and inflammatory mediators in the airways of subjects with severe asthma. Respir Med 2019; 150: 165-172
- 38 Froidure A, Mouthuy J, Durham SR, Chanez P, Sibille Y, Pilette C. Asthma phenotypes and IgE responses. Eur Respir J 2016; 47 (01) 304-319
- 39 Hartman JE, Srikanthan K, Caneja C. et al. Bronchoscopic targeted lung denervation in patients with severe asthma: preliminary findings. Respiration 2022; 101 (02) 184-189
- 40 Rönnebjerg L, Axelsson M, Kankaanranta H. et al. Severe asthma in a general population study: prevalence and clinical characteristics. J Asthma Allergy 2021; 14: 1105-1115
- 41 Figliozzi S, Masci PG, Ahmadi N. et al. Predictors of adverse prognosis in COVID-19: a systematic review and meta-analysis. Eur J Clin Invest 2020; 50 (10) e13362
- 42 Gompelmann D, Benjamin N, Bischoff E. et al. Survival after endoscopic valve therapy in patients with severe emphysema. Respiration 2019; 97 (02) 145-152
- 43 Garner JL, Kemp SV, Srikanthan K. et al. 5-year survival after endobronchial coil implantation: secondary analysis of the first randomised controlled trial, RESET. Respiration 2020; 99 (02) 154-162